Clinic Roundup

• Oncolytics Biotech Inc., of Calgary, Alberta, completed enrollment in the first stage of its Phase III trial examining Reolysin in combination with paclitaxel and carboplatin in 80 patients with platinum-refractory head and neck cancers.